Literature DB >> 36123445

The Evolution of Fluorescence-Guided Surgery.

Stan Van Keulen1, Marisa Hom2, Haley White2, Eben L Rosenthal2, Fred M Baik3.   

Abstract

There has been continual development of fluorescent agents, imaging systems, and their applications over the past several decades. With the recent FDA approvals of 5-aminolevulinic acid, hexaminolevulinate, and pafolacianine, much of the potential that fluorescence offers for image-guided oncologic surgery is now being actualized. In this article, we review the evolution of fluorescence-guided surgery, highlight the milestones which have contributed to successful clinical translation, and examine the future of targeted fluorescence imaging.
© 2022. The Author(s).

Entities:  

Keywords:  Fluorescence-guided surgery; Molecular imaging; Oncology

Year:  2022        PMID： 36123445     DOI： 10.1007/s11307-022-01772-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN： 1536-1632            Impact factor:   3.484


  50 in total

1.  Quirks of dye nomenclature. 9. Fluorescein.

Authors:  C J Cooksey
Journal:  Biotech Histochem       Date:  2017-09-14       Impact factor: 1.718

Review 2.  Fluorescein fundus photography (F.F.Ph.). A five year review (1960-1965).

Authors:  O M Ferrer
Journal:  Bibl Ophthalmol       Date:  1969

3.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results.

Authors:  Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440

4.  A histopathological appraisal of surgical margins in oral and oropharyngeal cancer resection specimens.

Authors:  Julia Anne Woolgar; Asterios Triantafyllou
Journal:  Oral Oncol       Date:  2005-08-29       Impact factor: 5.337

5.  Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors.

Authors:  Jordan Atkins; Fatema Al Mushawah; Catherine M Appleton; Amy E Cyr; William E Gillanders; Rebecca L Aft; Timothy J Eberlein; Feng Gao; Julie A Margenthaler
Journal:  J Surg Res       Date:  2012-04-10       Impact factor: 2.192

Review 6.  5-ALA and FDA approval for glioma surgery.

Authors:  Constantinos G Hadjipanayis; Walter Stummer
Journal:  J Neurooncol       Date:  2019-01-14       Impact factor: 4.130

7.  Frequency of positive surgical margin at prostatectomy and its effect on patient outcome.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Prostate Cancer       Date:  2011-06-09

Review 8.  Indications for fluorescein angiography in disease of the ocular fundus: a review.

Authors:  T J Ffytche; J S Shilling; I H Chisholm; J L Federman
Journal:  J R Soc Med       Date:  1980-05       Impact factor: 18.000

Review 9.  Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Authors:  Yair Lotan; Trinity J Bivalacqua; Tracy Downs; William Huang; Jeffrey Jones; Ashish M Kamat; Badrinath Konety; Per-Uno Malmström; James McKiernan; Michael O'Donnell; Sanjay Patel; Kamal Pohar; Matthew Resnick; Alexander Sankin; Angela Smith; Gary Steinberg; Edouard Trabulsi; Michael Woods; Siamak Daneshmand
Journal:  Nat Rev Urol       Date:  2019-06       Impact factor: 14.432

10.  Positive Surgical Margins in the 10 Most Common Solid Cancers.

Authors:  Ryan K Orosco; Viridiana J Tapia; Joseph A Califano; Bryan Clary; Ezra E W Cohen; Christopher Kane; Scott M Lippman; Karen Messer; Alfredo Molinolo; James D Murphy; John Pang; Assuntina Sacco; Kathryn R Tringale; Anne Wallace; Quyen T Nguyen
Journal:  Sci Rep       Date:  2018-04-09       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.